)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
SELLAS Life Sciences Group (SLS) investor relations material
SELLAS Life Sciences Group Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Focused on late-stage clinical development of cancer therapeutics, with lead candidates GPS and SLS009 targeting hematologic and solid tumors.
REGAL Phase 3 trial for GPS in AML ongoing, with interim analysis completed and final analysis expected by year-end 2025, pending event-driven criteria.
SLS009 Phase 2a trial in relapsed/refractory AML met all primary endpoints, with strong efficacy in biomarker-defined subgroups and FDA guidance to advance to first-line therapy study; new trial in first-line AML to begin Q1 2026.
Hosted a successful R&D Day highlighting GPS and SLS009 programs, with strong expert enthusiasm.
No product sales revenue; licensing revenue from 3D Medicines Agreement, with $191.5 million in potential future milestones.
Financial highlights
Net loss of $6.8 million for Q3 2025, improved from $7.1 million in Q3 2024; net loss of $19.2 million for nine months ended September 30, 2025, improved from $24.1 million year-over-year.
Operating expenses decreased to $7.1 million in Q3 2025 from $7.3 million in Q3 2024, and to $20.0 million for the nine months from $24.6 million year-over-year.
Cash and cash equivalents of $44.3 million as of September 30, 2025, with an additional $29.1 million raised in October 2025 from warrant exercises.
Accumulated deficit of $267.3 million as of September 30, 2025.
R&D expenses for Q3 2025 were $4.2 million, down from $4.4 million in Q3 2024; nine-month R&D expenses were $11.3 million, down from $14.7 million.
Outlook and guidance
Cash position, including October 2025 proceeds, expected to fund operations for at least the next twelve months.
Enrollment for an 80-patient trial of SLS009 in newly diagnosed and early refractory AML patients expected to begin in Q1 2026.
Anticipates increased R&D expenses as GPS approaches potential BLA filing and SLS009 advances to first-line AML trial.
May seek additional capital through equity, debt, or partnerships to support future operations.
Final analysis of the REGAL trial anticipated by year-end 2025, but timing may vary due to event-driven design.
SLS009 T-PLL data impact on future trials
Cash runway post-warrant exercises
What factors could delay REGAL final analysis?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next SELLAS Life Sciences Group earnings date
Q4 202518 Mar, 2026
Next SELLAS Life Sciences Group earnings date
Q4 202518 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
SELLAS Life Sciences Group Inc. is a biopharmaceutical company focused on developing immunotherapies for cancer. The company specializes in targeted peptide-based therapies designed to stimulate the immune system against various tumor types. Its research and development efforts aim to advance novel cancer treatments through clinical trials and regulatory approvals. The company is headquartered in Montvale, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage